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Cranial nerve
involvement in CMT
disease type 1 due to
early growth response
2 gene mutation
Article abstract—Mutations in the gene coding for the Schwann cell tran-
scription factor early growth response 2 (EGR2), which seems to regulate
myelinogenesis and hindbrain development, have been observed in few cases
of inherited neuropathy. The authors describe a unique combination of cra-
nial nerve deficits in one member of a Charcot-Marie-Tooth 1 family carrying
an EGR2 mutation (Arg381His). This finding further supports the role of
EGR2 in cranial nerve development. Key words: Charcot-Marie-Tooth dis-
ease—EGR2—Cranial nerves—Myelin genes—Demyelinating neuropathy.
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The demyelinating variety of Charcot-Marie-Tooth
disease (CMT1) is usually associated with a duplica-
tion on chromosome 17p11.2, encompassing the pe-
ripheral myelin protein 22 (PMP22) gene (CMT1A).
Micromutations involving the PMP22 gene or the
myelin protein zero gene (MPZ) (CMT1B) are rarely
found; the more common X-linked variety (CMTX) is
associated with connexin-32 mutations.1,2 In other
cases, no mutation is found. Some families do not
demonstrate linkage with any of these loci, providing
evidence for the existence of another locus (CMT1C).1
Mutations in the early growth response 2 gene
(EGR2) have been demonstrated in very few cases of
CMT1,3,4 Dejerine–Sottas disease (DSD),5,6 and con-
genital hypomyelinating neuropathy.3 EGR2 is a
Schwann cell transcription factor that binds DNA
through three zinc-finger domains,3 and is thought to
regulate the expression of late myelin genes such as
MPZ and myelin basic protein, thus playing a key
role in myelinogenesis.3 Homozygous mice knocked
out for Krox-20, the murine orthologue of EGR2,
have no compact myelin in the peripheral nervous
system.3 Moreover, they display abnormal rom-
bomere segmentation and neuronal migration in the
developing hindbrain, resulting in anatomic abnor-
malities of the cranial nerves, particularly of the V,
VI, VII, IX, and X pairs.3 Therefore, Krox-20 is
thought to mediate even hindbrain development.
We report the peculiar clinical features of a family
carrying a heterozygous missense EGR2 mutation
(Arg381His)6 and affected by severe CMT1 with a
unique combination of cranial nerve deficits in one
member.
Patients and methods. Two members of the family
were affected: the 67-year-old father and his 33-year-old
daughter. The father had gait abnormalities from infancy
and progressive wasting and weakness of distal limb mus-
cles, with later involvement of proximal muscles. He be-
came chairbound at age 55. During his 30s, he gradually
developed diplopia and strabismus and thereafter progres-
sive bilateral hearing loss. At age 62, he suddenly devel-
oped stridor and dyspnea and needed tracheostomy for
bilateral vocal cord palsy. At age 67, examination showed
weakness of left superior and medial rectus muscles with
diplopia on upward and lateral gaze toward right, consis-
tent with a partial palsy of the third cranial nerve. His
pupils were normal and he had severe bilateral hearing
loss. He still needed the tracheostomy tube, was dys-
phonic, and had very mild dyspnea. Stance and gait were
impossible. Upper limb weakness was mild proximally but
very severe distally; he was paraplegic with only incom-
plete thigh movements. Muscle wasting was severe in fore-
arms, hands, and lower limbs. Deep tendon reflexes
(DTRs) were absent. He had severe sensory loss to all
modalities with stocking-glove distribution and pes cavus
and achilles tendon tightening.
The daughter had a similar history of clumsy gait since
From the Departments of Neurology (Drs. Pareyson, Lauria, and Sghirlan-
zoni), Experimental Neurosciences (Drs. Taroni, Botti, and Baratta), Neuro-
pathology (Dr. Morbin), and Clinical Neurophysiology (Dr. Ciano), “C.
Besta” National Neurological Institute, Milan, Italy.
Supported by Telethon-Italy (grants to A.S., F.T.).
Presented in part at the ninth meeting of the European Neurological Soci-
ety (ENS); June 5–9, 1999; Milan, Italy.
Received November 29, 1999. Accepted in final form February 18, 2000.
Address reprint requests and correspondence to Dr. Davide Pareyson, De-
partment of Neurology, “C. Besta” National Neurological Institute, Via Ce-
loria 11, 20133 Milan, Italy; e-mail dpareys@tin.it
1696 Copyright © 2000 by the American Academy of Neurology
early childhood and a progressive sensorimotor deficit dis-
tally in all limbs. On examination, cranial nerves were nor-
mal. She had pes cavus and severe achilles tendon
tightening; without special shoes, she needed support to
walk. There was distal muscle wasting and weakness along
with sensory loss, moderate in upper limbs and severe in
lower limbs. DTRs were brisk but ankle jerks were absent.
Nerve conduction studies demonstrated marked slowing
of motor conduction velocities, which could be measured
only along radial nerves in the father (21 to 28 m/sec) and
in upper limb nerves in the daughter (16 to 24 m/sec). In
these nerves, distal motor latencies were prolonged (5 to 7
msec) and compound muscle action potential (CMAP) am-
plitudes were moderately to severely reduced. Apart from
the femoral nerve in the daughter, M-responses were ab-
sent in lower limb nerves. F-wave response could be ob-
tained only in the daughter’s median nerve (latency 5 51.2
msec). All sensory action potentials were absent. In both
patients, CMAP amplitudes were reduced and latencies
were prolonged in the facial and spinal accessory nerves;
blink reflex examination revealed prolongation of R1 (16.2
to 20 msec) and R2 (43.1 to 46.2 msec) responses.
Audiometry was performed in the father and showed 60
to 80 dB pantonal sensorineural hearing loss. Brainstem
auditory evoked potential (BAEP) studies revealed loss of
the early waves and severe bilateral delay of the V wave
latency (7.29 to 7.59 msec), which were consistent with the
audiometric findings and suggested a cochlear or retro-
choclear defect. BAEPs were normal in the daughter and
visual evoked potentials were normal in both patients.
Brain MRI was performed in both cases and failed to
reveal any abnormality in the brainstem or cranial nerves.
The daughter underwent sural nerve biopsy, which
showed severe loss of myelinated fibers and several onion-
bulb formations (figure, A). The few remaining fibers were
thinly or normally myelinated. On electron microscopy, on-
ion bulbs consisted of several lamellae of Schwann cell
cytoplasmic processes often containing unmyelinated ax-
ons; onion bulbs were denervated or they surrounded de-
remyelinated axons or fibers with normally compacted
myelin (see figure, B).
In both patients, direct sequencing analysis of EGR2
showed a heterozygous missense mutation (Arg381His) in
the second zinc-finger domain.6
Discussion. This family has severe CMT1 associ-
ated with a dominant heterozygous EGR2 mutation
in the second zinc-finger domain that probably im-
pairs interactions with DNA. The father showed a
unique combination of clinically overt cranial nerve
deficits: unilateral partial third nerve palsy, bilateral
palsy of the recurrent nerves leading to vocal cord
paresis requiring tracheostomy, and bilateral senso-
rineural hearing loss. Electrophysiologically, both
patients showed evidence of demyelination and ax-
onal loss along the VII and XI cranial nerves, and
also along the sensory trigeminal nerve fibers (as
shown by blink-reflex abnormalities). Audiometric
and BAEP findings were consistent with sensorineu-
ral hearing loss, although they could not discrimi-
nate between a cochlear and retrocochlear defect.
Electrophysiologic evidence of demyelination in
cranial nerves is expected in inherited demyelinating
neuropathies, such as CMT1 and DSD, characterized
by a generalized dysfunction of Schwann cell myelin.
Prolongation of BAEP early wave latencies is com-
mon in these diseases.7 However, the simultaneous
clinical involvement of different cranial nerves ob-
served in our patient is absolutely exceptional in
CMT1 and may be related to the role of Krox-20/
EGR2 in brainstem development. Patients with CMT
or DSD rarely show clinical cranial nerve involve-
ment. Trigeminal neuralgia (sometimes familial) has
been occasionally reported in CMT1 and DSD,8 and
weakness of masticatory or facial muscles is rarely
observed in DSD.9 Sensorineural hearing loss may
occur in CMT1.10 Even bulbar muscle weakness has
been reported as a rare manifestation of CMT1A10 or
DSD.9 Dysphonia due to partial vocal cord paresis
and dyspnea due to diaphragm weakness are exceed-
ingly rare.10 The axonal subtype CMT2C is charac-
terized by laryngeal recurrent and frenic nerve
involvement1,2; these nerves are rather long and pro-
gression of a length-dependent severe neuropathy
might explain their involvement.10 However, this
mechanism cannot explain either oculomotor nerve
palsy, which does not occur in CMT and DSD, or
sensorineural hearing loss. In our patient, involve-
ment of multiple cranial nerves seems to be associ-
ated with a specific EGR2 function. Consequently,
one might expect cranial nerve involvement to occur
at the nuclear level. However, because MRI was nor-
Figure. Daughter’s sural nerve biopsy.
(A) Semithin section. Severe loss of my-
elinated fibers, several onion-bulb for-
mations, few thinly myelinated fibers,
and a regenerating cluster are seen (to-
luidine blue; bar 5 20 mm). (B) Elec-
tron microscopy. A normally myelinated
fiber is surrounded by a multilayered
onion bulb consisting of Schwann cell
cytoplasmic processes often containing
unmyelinated axons (arrow) (uranyl
acetate and lead citrate; bar 5 2 mm).
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mal and we could not further localize the acoustic
defect, we could not establish whether cranial nerve
nuclei were primarily affected. One can hypothesize
that EGR2 mutation causes an underlying nuclear
defect that becomes clinically evident after prolonged
nerve trunk demyelination and axonal loss.
In the few reported patients carrying EGR2 muta-
tions, only the two DSD cases, who harbored the
same mutation, showed cranial nerve involvement5,6:
one had slight facial and masticatory muscle weak-
ness and the other only mild facial weakness.
Although the full spectrum of neuropathies associ-
ated with EGR2 mutations has yet to be defined,
cranial nerve abnormalities in the setting of a severe
demyelinating or hypomyelinating neuropathy
should raise the suspicion of an EGR2 mutation.
Note added in proof: We have become aware that Latour et al.
reported in an abstract the same EGR2 mutation in a 9-year-old
girl (J Periph Nerv Syst 1999;4:293–294). Interestingly, the pa-
tient had strabismus and nystagmus.
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Abnormalities in CSF
concentrations of
ferritin and
transferrin in
restless legs syndrome
Article abstract—CSF and serum were obtained from 16 patients with
idiopathic restless legs syndrome (RLS) and 8 age-matched healthy control
subjects. Patients with RLS had lower CSF ferritin levels (1.11 6 0.25 ng/mL
versus 3.50 6 0.55 ng/mL; p 5 0.0002) and higher CSF transferrin levels
(26.4 6 5.1 mg/L versus 6.71 6 1.6 mg/L; p 5 0.018) compared with control
subjects. There was no difference in serum ferritin and transferrin levels
between groups. The presence of reduced ferritin and elevated transferrin
levels in CSF is indicative of low brain iron in patients with idiopathic RLS.
Key words: Restless legs syndrome—Iron—Ferritin—Transferrin—CSF.
NEUROLOGY 2000;54:1698–1700
C.J. Earley, MD, PhD; J.R. Connor, PhD; J.L. Beard, PhD; E.A. Malecki, PhD; D.K. Epstein, MD;
and R.P. Allen, PhD
Restless legs syndrome (RLS) has been associated
commonly with iron deficiency.1,2 However, iron sup-
plementation even in RLS patients without iron defi-
ciency has been shown to produce improvement in
some patients.1,2 A plausible interpretation of these
results is that the management of iron in the brain is
altered in patients with RLS. This is possibly due to
the blood–brain barrier, which allows the brain to
maintain its iron status independent of blood levels.3
To determine whether brain iron status was altered
in RLS, we evaluated serum and CSF iron, ferritin,
and transferrin concentrations in patients with RLS
and control subjects.
Methods. We enrolled 16 patients with idiopathic RLS4
who had periodic leg movements in sleep of more than 15
per hour, a 1-year history of daily RLS symptoms, and a
positive clinical response to levodopa. Exclusion criteria
were iron deficiency (ferritin , 18 ng/dL), renal/metabolic
disorders, neuropathy, brain or spinal cord injuries,
chronic inflammatory processes, and chronic pain syn-
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